| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | GCLM; GLCLR; Glutamate--cysteine ligase regulatory subunit; GCS light chain; Gamma-ECS regulatory subunit; Gamma-glutamylcysteine synthetase regulatory subunit; Glutamate--cysteine ligase modifier subunit |
| Entrez GeneID | 2730 |
| WB Predicted band size | Calculated MW: 31 kDa; Observed MW: 31 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human GCLM |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇涉及GCLM抗体的文献概览(注：文献为虚拟示例，实际引用需核查真实数据库)：
1. **文献名称**: "GCLM modulates oxidative stress in Parkinson's disease models"
**作者**: Smith J, et al.
**摘要**: 本研究通过Western blot和免疫组化技术，利用GCLM特异性抗体，验证了帕金森病模型中GCLM蛋白表达下调与氧化损伤的相关性，提示其作为治疗靶点的潜力。
2. **文献名称**: "GCLM deficiency promotes chemoresistance in colorectal cancer"
**作者**: Chen L, et al.
**摘要**: 通过免疫荧光染色结合GCLM抗体，发现结直肠癌细胞中GCLM低表达导致谷胱甘肽合成减少，增强了化疗药物耐药性，为靶向代谢通路提供依据。
3. **文献名称**: "Tissue-specific regulation of GCLM in diabetic cardiomyopathy"
**作者**: Gupta R, et al.
**摘要**: 使用GCLM抗体进行心肌组织蛋白分析，揭示糖尿病小鼠心脏中GCLM表达受Nrf2通路调控，其失衡加剧了心肌氧化应激损伤。
---
**提示**：实际研究中建议通过PubMed或Web of Science检索最新文献，筛选方法部分含“anti-GCLM antibody”“Western blot/IHC”等关键词的研究，重点关注疾病机制或药物干预类论文。
The glutamate-cysteine ligase modifier subunit (GCLM) is a critical regulatory component of the glutamate-cysteine ligase (GCL) enzyme, which catalyzes the rate-limiting step in glutathione (GSH) biosynthesis. GCL comprises a catalytic subunit (GCLC) and a modifier subunit (GCLM), with GCLM enhancing enzymatic efficiency and stabilizing GCLC. As GSH is the primary cellular antioxidant, GCLM plays a pivotal role in maintaining redox homeostasis, detoxification, and cellular defense against oxidative stress.
GCLM antibodies are essential tools for studying the expression, localization, and regulation of GCLM in various biological contexts. They enable researchers to investigate GCLM's involvement in oxidative stress-related diseases, such as neurodegenerative disorders (e.g., Alzheimer’s and Parkinson’s), cardiovascular diseases, and cancer. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and ELISA to quantify GCLM levels in tissues or cells under physiological or pathological conditions.
Studies using GCLM antibodies have revealed that GCLM expression is modulated by oxidative stressors, inflammatory cytokines, and transcriptional regulators like Nrf2. Dysregulation of GCLM is linked to altered GSH levels, contributing to disease progression or therapeutic resistance. Furthermore, genetic polymorphisms in GCLM are associated with susceptibility to conditions like diabetes and chronic obstructive pulmonary disease (COPD). By enabling precise detection of GCLM, these antibodies support research into redox biology, disease mechanisms, and potential therapeutic strategies targeting GSH metabolism.
×
